Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, has said he will step down from the role in the coming months, kicking off the search for a successor. Dolsten’s ...

US pharmaceutical giant Pfizer on Tuesday said its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's Covid-19 vaccine, would step down. Dolsten will be ...

Boshoff replaces Mikael Dolsten, who led research and development at the drug giant for 15 years and who announced his plans to retire in July. The news may disappoint some investors, who may have ...

Pfizer Inc. (PFE) named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been ...

As we announced earlier this year, Dr. Mikael Dolsten, Pfizer's chief scientific officer, will depart from Pfizer after 15 years of leading Pfizer's research efforts. Our progress for selecting a ...